HM12460A clinical trials
Also written HM12460A.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses HM12460A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HM12460A
- 3
Studies by the year they started
3 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses HM12460A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes MellitusTerminatedPhase 1Hanmi Pharmaceutical Company LimitedNCT03332836Written as HM12460A
- Molar Potency Study of HM12460A in Healthy SubjectsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT03330314Written as HM12460A
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460ACompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01724814Written as HM12460A